Literature DB >> 9371517

Heparin/heparan sulfate interacting protein expression and functions in human breast cancer cells and normal breast epithelia.

A L Jacobs1, J Julian, A A Sahin, D D Carson.   

Abstract

Heparin/heparan sulfate interacting protein (HIP) is a recently identified protein expressed by many normal epithelia and epithelial cell lines. In the present study, we examined expression and potential functions of this protein in a series of human breast cancer cells and in sections of normal and malignant human breast tissue. Four of the five breast cancer cell lines studied (MCF-7, T-47D, MDA-MB468, and BT-549) expressed HIP protein and mRNA at similar levels. In contrast, MDA-MB-231 cells failed to display reactivity with HIP-specific probes in any assay. Cell aggregation assays and cell surface antibody binding studies demonstrated that HIP was expressed on the cell surface. However, HIP expression did not correlate with the number of cell surface [3H]heparin (HP) binding sites. The K(Dapp)s for cell surface HP binding sites were similar in all breast cancer cell lines studied and ranged from 112 to 298 nM. In contrast, cell surface HP binding capacity varied greatly, ranging from 2.3 x 10(5) (MDA-MB-231 and MDA-MB-468) to 99 x 10(5) sites/cell (BT-549). All cell lines tested displayed the ability to bind to a heparan sulfate (HS)-binding synthetic peptide motif of HIP in a HP-inhibitable fashion. Binding to this motif was not inhibited by other glycosaminoglycans including hyaluronic acid, chondroitin sulfates, or keratan sulfate. Furthermore, cell binding to HIP peptide was almost completely lost when intact cells were predigested with heparinases but not chondroitinases. Cell surface HS from breast cancer cells as well as normal human breast epithelia binded to HIP peptide in a HP-inhibitable fashion, demonstrating the ability of these cell surface components to directly interact. HIP was detected in both normal breast epithelia and breast tumors in situ. It is suggested that HIP mediates aspects of HS-dependent interactions of both normal and malignant breast epithelia with other cells and extracellular matrix components.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9371517

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  5 in total

1.  Perlecan domain I gradients establish stable biomimetic heparin binding growth factor gradients for cell migration in hydrogels.

Authors:  Kelsea M Hubka; Daniel D Carson; Daniel A Harrington; Mary C Farach-Carson
Journal:  Acta Biomater       Date:  2019-07-24       Impact factor: 8.947

2.  HIP/RPL29 antagonizes VEGF and FGF2 stimulated angiogenesis by interfering with HS-dependent responses.

Authors:  Sonia D'Souza; Weidong Yang; Dario Marchetti; Caroline Muir; Mary C Farach-Carson; Daniel D Carson
Journal:  J Cell Biochem       Date:  2008-12-01       Impact factor: 4.429

3.  Endogenous ribosomal protein L29 (RPL29): a newly identified regulator of angiogenesis in mice.

Authors:  Dylan T Jones; Tanguy Lechertier; Louise E Reynolds; Richard Mitter; Stephen D Robinson; Catherine B Kirn-Safran; Kairbaan M Hodivala-Dilke
Journal:  Dis Model Mech       Date:  2012-11-01       Impact factor: 5.758

4.  The interaction between LYVE-1 with hyaluronan on the cell surface may play a role in the diversity of adhesion to cancer cells.

Authors:  Yan Du; Hua Liu; Yiqing He; Yiwen Liu; Cuixia Yang; Muqing Zhou; Wenjuan Wang; Lian Cui; Jiajie Hu; Feng Gao
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

5.  Different cDNA microarray patterns of gene expression reflecting changes during metastatic progression in adenoid cystic carcinoma.

Authors:  Dan Huang; Wantao Chen; Ronggen He; Fan Yu; Zhiyuan Zhang; Weiliu Qiu
Journal:  World J Surg Oncol       Date:  2003-12-19       Impact factor: 2.754

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.